Lars Costers1, Jeroen Gielen2, Piet L Eelen3, Jeroen Van Schependom4, Jorne Laton2, Ann Van Remoortel3, Ellen Vanzeir5, Bart Van Wijmeersch6, Pierrette Seeldrayers7, Marie-Claire Haelewyck8, Miguel D'Haeseleer9, Marie-Beatrice D'hooghe9, Dawn Langdon10, Guy Nagels11. 1. Center for Neurosciences, Vrije Universiteit Brussel, Belgium. Electronic address: lcosters@vub.ac.be. 2. Center for Neurosciences, Vrije Universiteit Brussel, Belgium. 3. National MS Center Melsbroek, Belgium. 4. Center for Neurosciences, Vrije Universiteit Brussel, Belgium; Radiology, UZ Brussel, Vrije Universiteit Brussel, Belgium. 5. Revalidatie & MS Centrum Overpelt, Belgium. 6. Revalidatie & MS Centrum Overpelt, Belgium; Biomedisch Onderzoeksinstituut, Universiteit Hasselt, Belgium. 7. Centre Hospitalier Universitaire Charleroi, Belgium. 8. Faculté de Psychologie et des Sciences de l'Education, Université de Mons, Belgium. 9. Center for Neurosciences, Vrije Universiteit Brussel, Belgium; National MS Center Melsbroek, Belgium. 10. Royal Holloway, University of London, United Kingdom. 11. Center for Neurosciences, Vrije Universiteit Brussel, Belgium; Faculté de Psychologie et des Sciences de l'Education, Université de Mons, Belgium; National MS Center Melsbroek, Belgium.
Abstract
BACKGROUND: The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a fast, easy-to-administer and already widely validated neuropsychological battery for cognition in multiple sclerosis. OBJECTIVE: The goals of our study were to validate the BICAMS in a Belgian Dutch-speaking population and to investigate to what extent including extensive versions of two of the three BICAMS subtests improved its psychometric qualities. METHODS: Ninety-seven persons with MS and ninety-seven healthy controls were included and group-matched on age, education level and gender. All participants performed the BICAMS with an extensive version of the CVLT-II and BVMT-R. RESULTS: The SDMT and BVMT-R were able to dissociate between the MS and healthy control group, while the CVLT-II was not. Distributions of CVLT-II scores suggest learning effects in the MS group, indicating the need for alternative word lists or the construction of an adapted version fitted for repeated administration. Including the full CVLT-II and BVMT-R did not markedly improve the psychometric qualities of the BICAMS. CONCLUSION: This study validates the BICAMS in a Belgian Dutch-speaking population and facilitates the use of it in clinical practice, while providing evidence that including full versions of the CVLT-II and BVMT-R does not increase its psychometric qualities markedly.
BACKGROUND: The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a fast, easy-to-administer and already widely validated neuropsychological battery for cognition in multiple sclerosis. OBJECTIVE: The goals of our study were to validate the BICAMS in a Belgian Dutch-speaking population and to investigate to what extent including extensive versions of two of the three BICAMS subtests improved its psychometric qualities. METHODS: Ninety-seven persons with MS and ninety-seven healthy controls were included and group-matched on age, education level and gender. All participants performed the BICAMS with an extensive version of the CVLT-II and BVMT-R. RESULTS: The SDMT and BVMT-R were able to dissociate between the MS and healthy control group, while the CVLT-II was not. Distributions of CVLT-II scores suggest learning effects in the MS group, indicating the need for alternative word lists or the construction of an adapted version fitted for repeated administration. Including the full CVLT-II and BVMT-R did not markedly improve the psychometric qualities of the BICAMS. CONCLUSION: This study validates the BICAMS in a Belgian Dutch-speaking population and facilitates the use of it in clinical practice, while providing evidence that including full versions of the CVLT-II and BVMT-R does not increase its psychometric qualities markedly.
Authors: Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair Journal: Health Technol Assess Date: 2020-01 Impact factor: 4.014
Authors: Anthony Feinstein; Maria Pia Amato; Giampaolo Brichetto; Jeremy Chataway; Nancy Chiaravalloti; Ulrik Dalgas; John DeLuca; Peter Feys; Massimo Filippi; Jennifer Freeman; Cecilia Meza; Matilde Inglese; Robert W Motl; Maria Assunta Rocca; Brian M Sandroff; Amber Salter; Gary Cutter Journal: BMC Neurol Date: 2020-05-22 Impact factor: 2.474
Authors: Delphine Van Laethem; Alexander De Cock; Jeroen Van Schependom; Ralph H B Benedict; Guy Nagels; Marie D'hooghe Journal: Sci Rep Date: 2022-08-05 Impact factor: 4.996
Authors: Cláudia Sousa; Mariana Rigueiro-Neves; Telma Miranda; Paulo Alegria; José Vale; Ana Margarida Passos; Dawn Langdon; Maria José Sá Journal: BMC Neurol Date: 2018-10-17 Impact factor: 2.474
Authors: Lars Costers; Jeroen Van Schependom; Jorne Laton; Johan Baijot; Martin Sjøgård; Vincent Wens; Xavier De Tiège; Serge Goldman; Miguel D'Haeseleer; Marie Beatrice D'hooghe; Mark Woolrich; Guy Nagels Journal: Hum Brain Mapp Date: 2020-11-28 Impact factor: 5.038
Authors: Stijn Denissen; Oliver Y Chén; Johan De Mey; Maarten De Vos; Jeroen Van Schependom; Diana Maria Sima; Guy Nagels Journal: J Pers Med Date: 2021-12-11